AR045738A1 - Derivados de bencimidazol n3 alquilados como inhibidores de mek - Google Patents
Derivados de bencimidazol n3 alquilados como inhibidores de mekInfo
- Publication number
- AR045738A1 AR045738A1 ARP040103103A ARP040103103A AR045738A1 AR 045738 A1 AR045738 A1 AR 045738A1 AR P040103103 A ARP040103103 A AR P040103103A AR P040103103 A ARP040103103 A AR P040103103A AR 045738 A1 AR045738 A1 AR 045738A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- heteroaryl
- heterocyclyl
- nr3r4
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Abstract
Una prodroga de fosfato o aminoácido de un compuesto (1H-benzoimidazol-5-il) (fenil 4-sustituido)-amina alquilada que tiene la fórmula (1) y sales farmacéuticamente aceptables, prodrogas y solvatos de ellos, en donde: ------- es un enlace opcional, siempre que uno y sólo un N del anillo tenga enlace doble; R1, R9 y R10 ase seleccionan independientemente de H, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, - NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, -S(O)j(alquilo C1-6), -S(O)j(CR4R5)m-arilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -O(CR4R5)m-arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, -NR4(CR4R5)m-heteroarilo, -O(CR4R5)m-heterociclilo o -NR4(CR4R5)m-heterociclilo, donde cada porción de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a cinco grupos que se seleccionan independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, - NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R3 se selecciona de H, trifluorometilo, alquilo C1-10, alquenilo, C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a cinco grupos que se seleccionan independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, fosfato, residuo de aminoácido, polipéptido, hemisuccinato, ésteres de fosfato, dimetilaminoacetato, fosforilmetiloxicarbonilo, fosfonamida, -NR´SO2R""´, -SO2NR´R", -C(O)R´, -C(O)OR´, -OC(O)R´, -NR´C(O)OR"", -NR´C(O)R", -C(O)NR´R", -SR´, -S(O)R"", -SO2R"", - NR´R", -NR´C(O)NR"R"´, -NR¨C(NCN)NR"R"¨, -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo, o R3 y R4 junto con el átomo al cual están unidos forman un anillo carbocíclico, de heteroarilo o heterociclilo de 4 a 10 miembros, cada uno de los cuales se sustituye optativamente con uno a tres grupos que se seleccionan independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR´SO2R"", -SO2NR´R", -C(O)R´, - C(O)OR´, -OC(O)R´, -NR´C(O)OR"", -NR´C(O)R", -C(O)NR´R", - SO2R"", -NR´R", -NR´C(O)NR"R"´, -NR´C(NCN)NR"R"´, -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R´, R" y R"´se seleccionan independientemente de H, alquilo inferior, alquenilo inferior, arilo y arilalquilo; R"" se selecciona de alquilo inferior, alquenilo inferior, arilo y arilalquilo; o dos cualquiera de R´, R", R"´o R"" junto con el átomo al cual están unidos, forman un anillo carbocíclico, de heteroarilo o heterocíclico de 4 a 10 miembros, cada uno de los cuales se sustituye optativamente con uno a tres grupos que se seleccionan independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R4 y R5 representan independientemente H o alquilo C1-6, o R4 y R5 junto con el átomo al cual están unidos forman un anillo carbocíclico de heteroarilo o heterocíclico de 4 a 10 miembros, cada uno de los cuales se sustituye optativamente con uno a tres grupos que se seleccionan independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR´SO2R"", -SO2NR´R", -C(O)R´, -C(O)OR´, -OC(O)R´, -NR´C(O)OR"", -NR´C(O)R", -C(O)NR´R", - SO2R"", -NR´R", -NR´C(O)NR"R"´, -NR´C(NCN)NR"R"´, -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R6 se selecciona de trifluorometilo, alquilo C1-10, cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, en donde cada porción de alquilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a tres grupos oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR´SO2R"", -SO2NR´R", -C(O)R´, -C(O)OR´, -OC(O)R´, -NR´C(O)OR"", -NR´C(O)R", -C(O)NR´R", - SO2R"", - NR´R", -NR´C(O)NR"R"´, -NR´C(NCN)NR"R"´, -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R7 se selecciona, de alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3- 10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a cinco grupos que se seleccionan independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -SO2R6, -NR3R4, -NR5C(O)NR3R4, - NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; W se selecciona de heteroarilo, heterociclilo, -C(O)R3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(cicloalquilo C3-10), -C(O)(alquilo C1- 10), -C(O)(arilo), -C(O)(heteroarilo) y -C(O)(heterociclilo), cada uno de los cuales se sustituye optativamente con 1-5 grupos que se seleccionan de: -NR3R4, -OR3, -R2, alquilo C1-10, alquenilo C2-10, y alquinilo C2-10, cada uno de los cuales se sustituye optativamente con 1 o 2 grupos que se seleccionan independientemente de --NR3R4 y -OR3; R8 se selecciona de H, -SCF3, -Cl. -Br, -F, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -OR3, -C(O)R3, -C(O)OR3, - NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR3R4, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, S(O)j(alquilo C1-6), -S(O)j(CR4R5)m-arilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -O(CR4R5)m-arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, -NR4(CR4R5)m-heteroarilo, -O(CR4R5)m-heterociclilo o -NR4(CR4R5)m-heterociclilo, donde cada porción de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a cinco grupos que se seleccionan independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, - NR4SO2R6, SO2NE3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; m es 0, 1, 2, 3, 4º 5; y j es 1 o 2. Composición que comprende dicho compuesto y un portador farmacéuticamente aceptable. Uso de dicho compuesto para fabricar la composición farmacéutica útil para inhibir la actividad de MEK es un mamífero que lo necesita. Uso de dicho compuesto para fabricar una composición farmacéutica para el tratamiento de un trastorno hiperproliferativo en un mamífero que lo necesita mediante la administración de una cantidad eficaz para tratar ese trastorno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/652,733 US7235537B2 (en) | 2002-03-13 | 2003-08-29 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045738A1 true AR045738A1 (es) | 2005-11-09 |
Family
ID=34273411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103103A AR045738A1 (es) | 2003-08-29 | 2004-08-27 | Derivados de bencimidazol n3 alquilados como inhibidores de mek |
Country Status (18)
Country | Link |
---|---|
US (2) | US7235537B2 (es) |
EP (1) | EP1663210B1 (es) |
JP (1) | JP5026076B2 (es) |
KR (1) | KR20060121853A (es) |
CN (1) | CN1874768A (es) |
AR (1) | AR045738A1 (es) |
AU (1) | AU2004270166A1 (es) |
BR (1) | BRPI0413152A (es) |
CA (1) | CA2537098A1 (es) |
ES (1) | ES2628959T3 (es) |
IL (1) | IL173935A (es) |
IS (1) | IS8384A (es) |
MX (1) | MXPA06002268A (es) |
NO (1) | NO20061432L (es) |
RU (1) | RU2006109600A (es) |
TW (1) | TW200524879A (es) |
WO (1) | WO2005023251A1 (es) |
ZA (1) | ZA200602588B (es) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL401637A1 (pl) | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
CA2532067C (en) * | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005051302A2 (en) * | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
WO2005051304A2 (en) * | 2003-11-21 | 2005-06-09 | Array Biopharma Inc. | Akt protein kinase inhibitors |
KR20080019236A (ko) * | 2005-05-18 | 2008-03-03 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
NZ567140A (en) * | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
EP1971601B1 (en) | 2005-11-15 | 2009-10-21 | Array Biopharma Inc. | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
WO2007071951A1 (en) * | 2005-12-21 | 2007-06-28 | Astrazeneca Ab | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
ATE493418T1 (de) | 2006-07-06 | 2011-01-15 | Array Biopharma Inc | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren |
BRPI0713555A2 (pt) | 2006-07-06 | 2012-03-20 | Array Biopharma, Inc. | ciclopenta [d] pirimidinas como inibidores de akt protéina cinase |
SI2054418T1 (sl) | 2006-07-06 | 2012-02-29 | Array Biopharma Inc | Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji |
US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
WO2008016123A1 (fr) * | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
EP2099796B1 (en) * | 2006-11-30 | 2011-06-01 | Genentech, Inc. | Aza-indolyl compounds and methods of use |
US7999006B2 (en) * | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
CN101918373B (zh) * | 2007-07-05 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
KR20150089099A (ko) | 2007-07-05 | 2015-08-04 | 어레이 바이오파마 인크. | Akt 단백질 키나제 억제제로서의 피리미딜 시클로펜탄 |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
AU2008288556A1 (en) * | 2007-08-16 | 2009-02-19 | F. Hoffmann-La Roche Ag | Substituted hydantoins |
ES2456966T3 (es) | 2007-11-12 | 2014-04-24 | Takeda Pharmaceutical Company Limited | Inhibidores de MAPK/ERK cinasa |
WO2009074827A2 (en) * | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Combination comprising a mek inhibitor and an aurora kinase inhibitor 188 |
CA2707650A1 (en) | 2007-12-20 | 2009-07-02 | F. Hoffmann-La Roche Ag | Substituted hydantoins as mek kinase inhibitors |
JP5346345B2 (ja) * | 2008-01-09 | 2013-11-20 | アレイ バイオファーマ、インコーポレイテッド | Aktタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類 |
WO2009089453A1 (en) * | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
WO2010006225A1 (en) * | 2008-07-11 | 2010-01-14 | Novartis Ag | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway |
JP5746630B2 (ja) | 2008-11-10 | 2015-07-08 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換スルホンアミドフェノキシベンズアミド |
WO2011054620A1 (en) * | 2009-10-12 | 2011-05-12 | F. Hoffmann-La Roche Ag | Combinations of a pi3k inhibitor and a mek inhibitor |
CA2777304A1 (en) | 2009-10-21 | 2011-04-28 | Marion Hitchcock | Substituted benzosulphonamides |
EP2491014A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
CN103221043B (zh) | 2010-08-05 | 2016-04-06 | 卡斯西部储备大学 | 用于治疗神经元连接发育障碍的erk抑制剂 |
HUE033209T2 (hu) | 2010-10-06 | 2017-11-28 | Glaxosmithkline Llc | PI3 kináz inhibitor hatású benzimidazol-származékok |
US9045429B2 (en) | 2010-10-29 | 2015-06-02 | Bayer Intellectual Property Gmbh | Substituted phenoxypyridines |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
PL2655375T3 (pl) | 2010-12-23 | 2015-05-29 | Sanofi Sa | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
EP2694073B1 (en) | 2011-04-01 | 2018-08-08 | Genentech, Inc. | Combinations of akt and mek inhibitors for treating cancer |
CN107233343A (zh) | 2011-04-01 | 2017-10-10 | 基因泰克公司 | Akt抑制剂化合物和化疗剂的组合以及使用方法 |
ES2597052T3 (es) | 2011-05-25 | 2017-01-13 | Université Paris Descartes | Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal |
CN103764144B (zh) * | 2011-08-31 | 2016-07-20 | 诺华股份有限公司 | Pi3k抑制剂与mek抑制剂的协同组合 |
CN103204822B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途 |
EP2834237B1 (en) | 2012-03-14 | 2018-06-06 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | A novel process for the manufacture of compounds for use in the treatment of cancer |
ES2772498T3 (es) | 2012-10-19 | 2020-07-07 | Array Biopharma Inc | Preparación de un inhibidor mek y formulación que comprende el mismo |
WO2014097125A1 (en) * | 2012-12-20 | 2014-06-26 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
MA38522A1 (fr) | 2013-03-21 | 2017-10-31 | Novartis Ag | Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur. |
EP3043822A1 (en) | 2013-09-11 | 2016-07-20 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Compositions for preparing cardiomyocytes |
WO2016009306A1 (en) | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
WO2016035008A1 (en) | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
CN109890386B (zh) * | 2016-06-03 | 2022-05-24 | 阵列生物制药公司 | 药物组合 |
CN109438362B (zh) * | 2017-11-14 | 2020-07-21 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的苯并咪唑化合物及包含该化合物的组合物 |
TW202038957A (zh) | 2018-12-21 | 2020-11-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與激酶抑制劑之組合 |
US11447482B1 (en) | 2019-02-14 | 2022-09-20 | KUDA Therapeutics, Inc. | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis |
JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子 |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN115322105A (zh) * | 2021-05-11 | 2022-11-11 | 江苏润安制药有限公司 | 一种合成艾拉莫德关键中间体的方法 |
WO2022262699A1 (zh) * | 2021-06-17 | 2022-12-22 | 深圳市塔吉瑞生物医药有限公司 | 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途 |
AU2022306297A1 (en) | 2021-07-09 | 2024-02-08 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0710654A4 (en) * | 1993-07-23 | 1996-08-28 | Green Cross Corp | TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE |
US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6821963B2 (en) | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
NZ501277A (en) | 1997-07-01 | 2002-12-20 | Warner Lambert Co | -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
US6506798B1 (en) | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
PT993439E (pt) | 1997-07-01 | 2004-12-31 | Warner Lambert Co | Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek |
WO2000040237A1 (en) | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Antiviral method using mek inhibitors |
US6696440B1 (en) * | 1999-01-07 | 2004-02-24 | Warner-Lambert Company | Treatment of asthma with MEK inhibitors |
OA11819A (en) * | 1999-01-13 | 2005-08-17 | Warner Lambert Co | 1-Heterocycle substituted diarylamines. |
EP1144385B1 (en) | 1999-01-13 | 2005-08-17 | Warner-Lambert Company Llc | Benzoheterocycles and their use as mek inhibitors |
EP1150950A2 (en) | 1999-01-13 | 2001-11-07 | Warner-Lambert Company | Anthranilic acid derivatives |
EP1144371B1 (en) * | 1999-01-13 | 2005-11-09 | Warner-Lambert Company Llc | Benzenesulphonamide derivatives and their use as mek inhibitors |
CA2349467A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
US7030119B1 (en) * | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
CA2378381A1 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
CA2377092A1 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
NZ515567A (en) | 1999-07-16 | 2004-03-26 | Warner Lambert Co | Method for treating chronic pain using MEK inhibitors |
HUP0202381A3 (en) | 1999-07-16 | 2004-12-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
CA2403017A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
EP1339702A1 (en) * | 2000-03-15 | 2003-09-03 | Warner-Lambert Company | 5-amide substituted diarylamines as mek inhibitors |
EE05450B1 (et) | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
AP2001002249A0 (en) | 2000-08-25 | 2001-09-30 | Warner Lambert Co | Process for making N-ARYL-ANTHRANILIC acids and their derivatives. |
EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
MXPA04008894A (es) * | 2002-03-13 | 2005-06-20 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilados como inhibidores de mek. |
PL401637A1 (pl) * | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
CA2532067C (en) * | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
-
2003
- 2003-08-29 US US10/652,733 patent/US7235537B2/en not_active Expired - Lifetime
-
2004
- 2004-08-20 WO PCT/US2004/027199 patent/WO2005023251A1/en active Application Filing
- 2004-08-20 AU AU2004270166A patent/AU2004270166A1/en not_active Abandoned
- 2004-08-20 ES ES04781809.1T patent/ES2628959T3/es active Active
- 2004-08-20 ZA ZA200602588A patent/ZA200602588B/en unknown
- 2004-08-20 MX MXPA06002268A patent/MXPA06002268A/es unknown
- 2004-08-20 CA CA002537098A patent/CA2537098A1/en not_active Abandoned
- 2004-08-20 RU RU2006109600/04A patent/RU2006109600A/ru not_active Application Discontinuation
- 2004-08-20 JP JP2006524761A patent/JP5026076B2/ja active Active
- 2004-08-20 CN CNA2004800323322A patent/CN1874768A/zh active Pending
- 2004-08-20 BR BRPI0413152-5A patent/BRPI0413152A/pt not_active Application Discontinuation
- 2004-08-20 EP EP04781809.1A patent/EP1663210B1/en active Active
- 2004-08-20 TW TW093125125A patent/TW200524879A/zh unknown
- 2004-08-20 KR KR1020067004187A patent/KR20060121853A/ko not_active Application Discontinuation
- 2004-08-27 AR ARP040103103A patent/AR045738A1/es not_active Application Discontinuation
-
2006
- 2006-02-26 IL IL173935A patent/IL173935A/en active IP Right Grant
- 2006-03-29 IS IS8384A patent/IS8384A/is unknown
- 2006-03-29 NO NO20061432A patent/NO20061432L/no not_active Application Discontinuation
-
2007
- 2007-06-14 US US11/762,897 patent/US7842816B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US7842816B2 (en) | 2010-11-30 |
TW200524879A (en) | 2005-08-01 |
AU2004270166A1 (en) | 2005-03-17 |
EP1663210A4 (en) | 2009-04-22 |
EP1663210B1 (en) | 2017-04-19 |
MXPA06002268A (es) | 2006-05-31 |
WO2005023251A1 (en) | 2005-03-17 |
IL173935A0 (en) | 2006-07-05 |
JP2007504139A (ja) | 2007-03-01 |
BRPI0413152A (pt) | 2006-10-03 |
EP1663210A1 (en) | 2006-06-07 |
NO20061432L (no) | 2006-08-25 |
ZA200602588B (en) | 2008-07-30 |
US20070299063A1 (en) | 2007-12-27 |
ES2628959T3 (es) | 2017-08-04 |
IL173935A (en) | 2015-08-31 |
US20040116710A1 (en) | 2004-06-17 |
CA2537098A1 (en) | 2005-03-17 |
JP5026076B2 (ja) | 2012-09-12 |
RU2006109600A (ru) | 2007-10-10 |
KR20060121853A (ko) | 2006-11-29 |
IS8384A (is) | 2006-03-29 |
US7235537B2 (en) | 2007-06-26 |
CN1874768A (zh) | 2006-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045738A1 (es) | Derivados de bencimidazol n3 alquilados como inhibidores de mek | |
AR038971A1 (es) | Derivados de bencimidazol n3 alquilado como inhibidores de mek | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
AR051403A1 (es) | Derivados de purina, purinona y deazapurina como inhibidores de la actividad de la protein quinasa; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la protein quinasa a y b. | |
AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
AR038972A1 (es) | Derivados de bencimidazol n3 alquilado como inhibidores de mek | |
AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
AR039673A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion | |
AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR038883A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos | |
AR044134A1 (es) | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. | |
EA202090658A1 (ru) | Ингибиторы кэп-зависимой эндонуклеазы | |
AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
BRPI0619823A8 (pt) | compostos que são inibidores de erk | |
AR046272A1 (es) | Inhibidores de dipeptidil peptidasa iv | |
BR112015015812A2 (pt) | derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor | |
AR043199A1 (es) | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes | |
AR046081A1 (es) | Inhibidores heterociclicos de mek y uso de los mismos | |
UY28144A1 (es) | Agentes terapéuticos | |
BRPI0519287A2 (pt) | derivados de amida | |
AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
DE602005016261D1 (de) | Substituierte arylaminderivate und verwendungsverfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal | ||
FA | Abandonment or withdrawal | ||
FB | Suspension of granting procedure |